OneSource partners with Formycon AG for biosimilar manufacturing

Marquee Jv AnnouncedStrategic Transactions View source PDF

ONESOURCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-2.1%1-day move

₹1671.90

prior close

₹1677.60

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.4+0.0-0.6-1.4-2.1-1.4-1.7+0.8-1.5-1.9————

Up moveDown movePending

AI summary

OneSource Specialty Pharma announced a strategic manufacturing partnership with Formycon AG, a German biosimilar developer listed on the Frankfurt Stock Exchange. OneSource will provide integrated Drug Substance and Drug Product manufacturing from its Bangalore biologics facility for Formycon's biosimilar programs targeting global markets. Formycon already has three biosimilars on market and a pipeline including pembrolizumab and dupilumab biosimilars. OneSource operates five manufacturing facilities approved by US FDA and EMA, with over 1,600 professionals. No financial terms disclosed.

Likely market impact

Strengthens biologics franchise with a marquee global partner, supports future order book. No immediate financial impact disclosed.